During the recent session, Portage Biotech Inc (NASDAQ:PRTG)’s traded shares were 21.03 million, with the beta value of the company hitting 1.51. At the last check today, the stock’s price was $9.81, reflecting an intraday gain of 108.29% or $5.1. The 52-week high for the PRTG share is $23.01, that puts it down -134.56 from that peak though still a striking 78.59% gain since the share price plummeted to a 52-week low of $2.10. The company’s market capitalization is $11.00M, and the average intraday trading volume over the past 10 days was 0.22 million shares, and the average trade volume was 101.95K shares over the past three months.
Portage Biotech Inc (PRTG) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 3.00. PRTG has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 0.
Portage Biotech Inc (NASDAQ:PRTG) trade information
Portage Biotech Inc (PRTG) registered a 108.29% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 108.29% in intraday trading to $9.81, hitting a weekly high. The stock’s 5-day price performance is 136.40%, and it has moved by 126.05% in 30 days. Based on these gigs, the overall price performance for the year is -7.45%. The short interest in Portage Biotech Inc (NASDAQ:PRTG) is 13819.0 shares and it means that shorts have 0.69 day(s) to cover.
The consensus price target of analysts on Wall Street is $4.88, which implies a decrease of -101.02% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $4.5 and $5.25 respectively. As a result, PRTG is trading at a premium of 46.48% off the target high and 54.13% off the low.
PRTG Dividends
Portage Biotech Inc is due to release its next quarterly earnings on 2024-Feb-27. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Portage Biotech Inc (NASDAQ:PRTG)’s Major holders
Portage Biotech Inc insiders own 51.38% of total outstanding shares while institutional holders control 6.20%, with the float percentage being 12.74%. ARMISTICE CAPITAL, LLC is the largest shareholder of the company, while 20.0 institutions own stock in it. As of 2024-06-30, the company held over 1.5 million shares (or 7.1866% of all shares), a total value of $0.32 million in shares.
The next largest institutional holding, with 0.3 million shares, is of ‘s that is approximately 1.4247% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $71514.0.
Also, the Mutual Funds coming in first place with the largest holdings of Portage Biotech Inc (PRTG) shares are Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund and Guggenheim Active Allocation Fund. Data provided on Dec 31, 2024 indicates that Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund owns about 107.0 shares. This amounts to just over 0.01 percent of the company’s overall shares, with a $1022.0 market value. The same data shows that the other fund manager holds slightly less at 1.0, or about 0.00% of the stock, which is worth about $9.0.
